SCHEMBL5688252

SCHEMBL5688252

Cc1ccc(CCc2ccc(OC(=O)N3CCC(COn4cccn4)CC3)cc2)nc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.44
AOC3 Q16853 1/20 0.40
LIPE Q05469 2/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.35
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
NPY2R P49146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5687951 0.92 GRIN2B (0.44) GRIN2BLIPENPC1RAB9ACYP4F2
SCHEMBL5688040 0.88 GRIN2B (0.42) GRIN2BLIPENPC1RAB9AGAA
SCHEMBL5687592 0.88 AOC3 (0.40) GRIN2BAOC3LIPENPC1RAB9A
SCHEMBL5688925 0.85 GRIN2B (0.41) GRIN2BAOC3LIPECYP4F2CYP4A11
SCHEMBL5688587 0.85 GRIN2B (0.38) GRIN2BNPC1RAB9AGAA
SCHEMBL5688116 0.83 GRIN2B (0.42) GRIN2BLIPENPC1RAB9AGAA
SCHEMBL5688640 0.82 GRIN2B (0.42) GRIN2BLIPENPC1RAB9AGAA
SCHEMBL5931578 0.81 GRIN2B (0.43) GRIN2BAOC3LIPECYP4F2CYP4A11
SCHEMBL5688089 0.81 GRIN2B (0.43) GRIN2BAOC3LIPENPC1RAB9A
SCHEMBL5931494 0.81 LIPE (0.51) GRIN2BAOC3LIPECYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC GRIN2B 2588/4885AOC3 1480/4885LIPE 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.